Emerging pharmacological therapies for fibromyalgia.

LAWSON, Kim (2006). Emerging pharmacological therapies for fibromyalgia. Current Opinion in Investigational Drugs, 7 (7), 631-636.

Full text not available from this repository.


Fibromyalgia is a chronic pain disorder for which pathophysiological mechanisms are difficult to identify and current drug therapies demonstrate limited effectiveness and significant tolerability. To date, no drugs have been officially approved for the indication of fibromyalgia, and randomized, controlled clinical trials with fibromyalgia patients are taking place to identify potential therapeutic approaches. Although emerging therapies, such as the antidepressants duloxetine and milnacipran and the antiepileptic pregabalin, offer certain efficacy, randomized controlled trials are generally difficult due to factors such as a lack of understanding of the pathophysiology and a heterogenous fibromyalgia patient population. For a significant advance in the drug treatment of fibromyalgia, novel clues are still awaited that may offer an effective therapeutic approach.

Item Type: Article
Research Institute, Centre or Group - Does NOT include content added after October 2018: Biomedical Research Centre
Page Range: 631-636
Depositing User: Jamie Young
Date Deposited: 28 May 2015 11:35
Last Modified: 18 Mar 2021 18:46
URI: https://shura.shu.ac.uk/id/eprint/9912

Actions (login required)

View Item View Item


Downloads per month over past year

View more statistics